An open label, dose escalation study to evaluate safety, tolerability, and pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) [OCX 0191] in cancer patients using a single daily dose for five days
Latest Information Update: 18 Jul 2013
At a glance
- Drugs OCX 191 (Primary)
- Indications Breast cancer; Colorectal cancer; Lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Sep 2005 New trial record.